Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Anthropic IPO Marketing Expected to Start in Mid-October 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Milei Threatens Falkland Oil Firms With Sanctions 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Add as a preferred source on Google
BOTHELL, Wash., Feb. 19, 2018 -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will report its fourth quarter and year-end 2017 financial and operating results after the close of U.S. financial markets on Monday, February 26, 2018. Alder management will host a conference call and live audio webcast to discuss the results and provide a general business update at 5:00 p.m. ET the same day.
The live call may be accessed by dialing (877) 430-4657 for domestic callers or (484) 756-4339 for international callers, and providing conference ID number 6943609. The webcast and any accompanying slides can be accessed from the Events & Presentations page in the investors section of Alder's website at www.alderbio.com and will be available for replay following the call for at least 30 days.
About Alder BioPharmaceuticals, Inc.
Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company committed to transforming the treatment paradigm for patients with migraine and other serious neurological or inflammatory conditions. Leveraging its pioneering monoclonal antibody technologies, Alder discovers and develops novel therapeutic antibodies designed to deliver highly differentiated, best-in-class clinical profiles. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated as potentially the first-to-market migraine prevention infusion therapy. Eptinezumab is a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide (CGRP), which is believed to play a key role in mediating and initiating migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc. For more information, please visit http://www.alderbio.com.
Media Contact:
Ashley Cadle
TogoRun
310-463-0143
[email protected]
Investor Relations Contact:
Michael Schaffzin
Stern Investor Relations, Inc.
212-362-1200
[email protected]
